Inactive Instrument

Biostar Pharmaceuticals, Inc. Stock Nasdaq

US0906781036

Pharmaceuticals

End-of-day quote Nasdaq
- ^USD	-

25-09-15	Biostar Pharma, Inc. Successively Achieves First Patient Dosing for Two Phase II/III Multiregional Clinical Trials of Utidelone Capsule	CI
23-06-15	Biostar Pharmaceuticals, Inc. Announces FDA Approval of Utidelone Injectable Phase 2/3 Multi-National Clinical Trial for Non-Small Cell Lung Cancer	CI

Valuation: Biostar Pharmaceuticals, Inc.

Market Cap	4.67M 4.16M 3.88M 3.53M 6.65M 450M 6.7M 46.88M 18.24M 229M 17.52M 17.14M 738M	P/E 2015	-0.25x	P/E 2016	-1.17x
Enterprise Value	6.82M 6.08M 5.67M 5.16M 9.71M 657M 9.79M 68.49M 26.65M 335M 25.6M 25.05M 1.08B	EV / Sales 2015	0.33x	EV / Sales 2016	4.14x
Free-Float	100%	Yield 2015 *	-	Yield 2016	-

* Estimated data More valuation ratios

Latest news: Biostar Pharmaceuticals, Inc.

25-09-15	Biostar Pharma, Inc. Successively Achieves First Patient Dosing for Two Phase II/III Multiregional Clinical Trials of Utidelone Capsule	CI
23-06-15	Biostar Pharmaceuticals, Inc. Announces FDA Approval of Utidelone Injectable Phase 2/3 Multi-National Clinical Trial for Non-Small Cell Lung Cancer	CI
23-06-12	Biostar Pharma, Inc. Announces First Patient Enrolled for Phase 1 Study of Utidelone Capsule	CI
19-06-01	Waiping Liu cancelled the acquisition of 16.2% stake in Biostar Pharmaceuticals, Inc. from Ronghua Wang.	CI
18-09-18	Biostar Pharmaceuticals, Inc.(NasdaqCM:BSPM) dropped from NASDAQ Composite Index	CI
18-07-02	Waiping Liu Discloses its Plans on Biostar Pharmaceuticals	CI
18-07-01	Waiping Liu entered into share purchase agreement to acquire 16.2% stake in Biostar Pharmaceuticals, Inc. from Ronghua Wang for $0.67 million.	CI
18-02-02	Biostar Pharmaceuticals, Inc. Announces Board Changes	CI
17-12-28	Biostar Pharmaceuticals, Inc. Appoints Melissa Fan Chen as an Independent Member of the Board and the Chair of the Audit Committee	CI
17-12-18	Biostar Pharmaceuticals, Inc. Announces Resignation of Leung King Fai as an Independent Director	CI
17-11-20	Biostar Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017	CI
17-11-15	Biostar Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017	CI
17-11-15	Biostar Pharmaceuticals Seeks Acquisitions	CI

More news

Managers and Directors: Biostar Pharmaceuticals, Inc.

Manager	Title	Age	Since
Rong Hua Wang CEO	Chief Executive Officer	71	2007-03-26
Xiaojuan Zhai DFI	Director of Finance/CFO	-	2017-02-04
Zheng Hong Wang COO	Chief Operating Officer	45	2012-03-25

Director	Title	Age	Since
Rong Hua Wang CHM	Chairman	71	2007-03-26
Hai Peng Wu BRD	Director/Board Member	68	2010-01-04
Zhan Xiang Ma BRD	Director/Board Member	-	2018-01-28

More insiders

Biostar Pharmaceuticals, Inc. (Biostar) is a holding company. The Company, through its subsidiary, Shaanxi Biostar Biotech, Ltd. (Shaanxi Biostar), and its variable interest entities (VIEs), Shaanxi Aoxing Pharmaceutical Co., Ltd. (Aoxing Pharmaceutical) and Shaanxi Weinan Huaren Pharmaceuticals Ltd. (Shaanxi Weinan), develops, manufactures and markets pharmaceutical products for various diseases and conditions in the People's Republic of China (PRC or China). The Company offers over-the-counter (OTC) products and prescription-based pharmaceuticals. The Company's products are sold in approximately 30 provinces in the PRC through a network of over 60 distributors and through approximately 230 sales people. The Company's products include XinAoxing Oleanolic Acid Capsule, Ganwang Compound Paracetamol Capsule, Tianqi Dysmenorrhea Capsule, Compound Paracetamol and Amantadine Hydrochloride Tablets, Deafness Tongqiao pills and Huangyangning Tablets.

Employees

Sector

Pharmaceuticals

More about the company

Rankings

Rankings

Currency / Forex

Commodities

Cryptocurrencies

Interest Rates

The best tools reserved for subscribers to boost the performance of your investments!

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	+0.82%	-3.01%	+35.98%	+112.22%	1,019B
JOHNSON & JOHNSON	-0.61%	-6.63%	+34.95%	+61.59%	617B
ABBVIE INC.	+0.12%	-1.20%	+14.29%	+78.42%	464B
MERCK & CO., INC.	-3.12%	-6.05%	+57.31%	+34.84%	356B
ROCHE HOLDING AG	+0.93%	-1.83%	+20.98%	+41.43%	333B
NOVARTIS AG	+0.12%	-4.05%	+10.09%	+33.53%	267B
ASTRAZENECA PLC	-0.89%	-5.83%	-7.56%	+7.91%	244B
AMGEN INC.	-0.46%	-4.11%	+36.32%	+51.26%	218B
GILEAD SCIENCES, INC.	-0.44%	-5.52%	+26.62%	+92.52%	179B
Average	-0.47%	-3.54%	+25.44%	+57.08%	410.8B
Weighted average by Cap.	-0.23%	-3.54%	+28.62%	+68.59%

	2015	2016
Net sales	27.13M 24.2M 22.55M 20.52M 38.64M 2.61B 38.93M 272M 106M 1.33B 102M 99.65M 4.29B	2.38M 2.13M 1.98M 1.8M 3.4M 230M 3.42M 23.95M 9.32M 117M 8.95M 8.76M 377M
Net income	-25.11M -22.4M -20.87M -18.99M -35.77M -2.42B -36.03M -252M -98.12M -1.23B -94.27M -92.24M -3.97B	-5.7M -5.08M -4.74M -4.31M -8.12M -549M -8.18M -57.23M -22.26M -280M -21.39M -20.93M -900M
Net Debt	2.73M 2.44M 2.27M 2.07M 3.89M 263M 3.92M 27.46M 10.68M 134M 10.26M 10.04M 432M	2.15M 1.92M 1.79M 1.63M 3.07M 207M 3.09M 21.62M 8.41M 106M 8.08M 7.91M 340M

Biostar Pharmaceuticals, Inc. Stock Nasdaq

Stocks

US0906781036

Pharmaceuticals

Valuation: Biostar Pharmaceuticals, Inc.

Latest news: Biostar Pharmaceuticals, Inc.

Managers and Directors: Biostar Pharmaceuticals, Inc.

Other Pharmaceuticals

Financials

Company Profile